Stage IV/Recurrent Esophageal Cancer


Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

New Drug Combination Boosts Survival in Advanced Stomach and Esophageal Cancers (July 1, 2015)

Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination.... Continue Reading

National Esophageal Cancer Awareness Month on CancerConnect (April 6, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of esophageal cancer educational programs for national esophageal cancer awareness month. As the month of April... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of... Continue Reading

Esophageal Cancer Survival Improved Using Targeted Therapy Developed in Lung Cancer (December 4, 2014)

Targeted therapy commonly used in lung cancer improves survival of esophageal cancer patients according to clinical trial results recently presented at the National Cancer Research Institute (NCRI) Cancer... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (November 13, 2014)

The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource... Continue Reading

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer (April 3, 2013)

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers... Continue Reading

Surgery Improves Survival in Esophageal Cancer (February 21, 2013)

Surgery after chemoradiotherapy—which is the standard of care in advanced esophageal cancer—increased overall and disease-free survival compared with chemoradiotherapy alone, according to the results... Continue Reading

Iressa Improves Progression-Free Survival in Metastatic Esophageal Cancer (October 5, 2012)

Treatment with Iressa® (gefitinib) slowed disease progression and improved quality of life in patients with metastatic esophageal cancer, according to the results of a phase III trial presented at the... Continue Reading

Factors Affecting Quality of Life at the End of Life (July 20, 2012)

For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

Some Patients with Advanced Cancer Continue Screening (October 22, 2010)

A significant proportion of patients with advanced cancers continue to undergo cancer screening, even though screening is unlikely to benefit these patients. These findings were recently reported in the... Continue Reading

Depression May Persist With Metastatic Cancer (May 27, 2010)

A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early... Continue Reading

Xeloda® and Eloxatin® Evaluated in Esophageal and Gastric Cancers (January 4, 2008)

Xeloda® and Eloxatin® Evaluated in Esophageal and Gastric Cancers According to the results of a Phase III clinical trial published in the New England Journal of Medicine, it may be possible to replace... Continue Reading

Selected Subsets of Patients with Esophageal Cancer Respond to Iressa® (April 11, 2006)

Selected Subsets of Patients with Esophageal Cancer Respond to Iressa® Among patients with advanced esophageal cancer, treatment with Iressa® (gefitinib) produced better results in women, in patients... Continue Reading

Advexin® Promising for Inoperable, Refractory Esophageal Cancer (March 20, 2006)

Advexin® Promising for Inoperable, Refractory Esophageal Cancer According to a press release by Introgen Therapeutics, Inc., the vaccine Advexin® appears promising as single-agent therapy in patients... Continue Reading

Improved Survival After Surgery for Esophageal Cancer (November 28, 2005)

Improved Survival After Surgery for Esophageal Cancer Survival after surgery for esophageal cancer improved significantly between 1987 and 2000, according to the results of a study published in the journal... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS